Rakuten Medical

Attending #BIOAsiaTaiwan2024? Rakuten Medical's Chief of Staff Louise Chang will present at BIO Asia–Taiwan in Taipei.   Stop by Room 402A, 4F, TaiNEX at 12:00 PM, July 25 to learn more about our investigational #Alluminox™ platform.

楽天メディカルはスポーツを通じた啓発活動を行っており、多くの方に頭頸部がんについて知っていただく機会として、7月27日の「世界頭頸部がんの日」に楽天イーグルスの一軍公式戦に冠協賛します。同日、日本頭頸部癌学会と連携のもと「楽天メディカル 頭頸部がん克服デー」を開催します！   頭頸部がんの認知度向上や予防・早期発見に繋げるため、楽天メディカルが日本頭頸部癌学会監修のもと制作した、楽天イーグルスの選手を起用したオリジナル付箋やクリアファイルを球場で配布！ぜひ、遊びに来てください⚾   ◆イベントの詳細は👇 https://lnkd.in/gTGEyBxB   #rakutenmedical #conqueringcancer #RakutenEagles

Join us on Thursday, June 20 at 1:00 pm ET / 10:00 am PT for Rakuten Medical’s virtual R&D Day, featuring Dr. Ann Gillenwater (MD Anderson Cancer Center), discussing the interim evaluation update of the Phase 1b/2 clinical trial of #photoimmunotherapy based on #Alluminox™ platform using ASP-1929 in combination with anti-PD-1 therapy in first line recurrent and/or metastatic Head and Neck Squamous Cell Carcinoma.   Register here: https://lnkd.in/gWmJPTzb Learn more at: https://lnkd.in/gVfYgw4f

Overall survival rate estimated at 24 months was 52.4% with generally tolerated safety profile. At #ASCO24, Dr. David Cognetti presented the updated safety and efficacy findings from an interim evaluation of Rakuten Medical’s open-label Phase 1b/2 study of #photoimmunotherapy using ASP-1929 in combination with anti-PD-1 for recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). Based on these results, Rakuten Medical plans to initiate a new phase 3 clinical trial with a primary endpoint of OS in the second half of 2024. Learn more: https://lnkd.in/gBjPvGzi #Alluminox

Rakuten Medical' s poster presentation at #ASCO24 will be taking place tomorrow.

Attending #BIO2024? Rakuten Medical COO Abhijit Bhatia, MS, MBA will present at BIO International Convention in San Diego.   Stop by Company Presentation Theater 1 at 12:15 PM, June 5 to learn more about our investigational #Alluminox platform.   We are happy to connect and explore potential partnerships. Please don't hesitate to reach out to us at partnerships@rakuten-med.com.

Join us for a virtual R&D Day at which Rakuten Medical will share interim evaluation update of the Phase 1b/2 clinical trial of #photoimmunotherapy based on #Alluminox™ platform using ASP-1929 in combination with anti-PD-1 therapy in first line recurrent and/or metastatic Head and Neck Squamous Cell Carcinoma. Register here: https://lnkd.in/gWmJPTzb Learn more at: https://lnkd.in/gVfYgw4f

Thank you Nasdaq for celebrating Rakuten Medical’s announcement of recent interim data from Phase 1b/2 study of ASP-1929 #photoimmunotherapy in combination with anti-PD-1 for the first-line recurrent and/or metastatic head and neck. We look forward to sharing this exiting data with global oncology experts at #ASCO24. Learn more at: https://lnkd.in/gBjPvGzi   #Alluminox™  

Overall survival rate estimated at 24 months was 52.4% with generally tolerated safety profile. Rakuten Medical is excited to announce the updated safety and efficacy findings from an interim evaluation of an open-label Phase 1b/2 study of #photoimmunotherapy using ASP-1929 in combination with anti-PD-1 for first-line recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). The data will be presented in a poster at #ASCO24. Rakuten Medical recently completed a Type B End-of-Phase 2 (EOP2) meeting with the US FDA for the combination of ASP-1929 photoimmunotherapy and anti-PD-1 in the first-line recurrent HNSCC setting and discussed the key details for a multi-regional registrational study. Rakuten Medical plans to initiate this global phase 3 clinical trial with a primary endpoint of OS in the second half of 2024. Learn more: https://lnkd.in/gBjPvGzi #Alluminox